Altitude Online: The Business of Neuroscience & Psychedelics
"I want visitors to the exhibition to remember that your difference is your power. It is a precious and beautiful thing." — Tim Walker
Psychedelics
The NYT Put Numbers on Ketamine's Danger Zone: A Clinical Dose Is 30–150mg, Recreational Users Reported Taking 1,000
"The dose makes the poison," The New York Times' Andrew Jacobs wrote this week, revisiting the pharmacology question at the center of the Cornell lawsuit we...
The New York Times • Oct 10, 2026
Policy
Meet the 7 People Who Actually Lobby for Psychedelics in Washington
Policy
Only 3 of 10 Psychedelic Companies Lobby Washington. One Just Joined — Twice, in the Same Quarter.
Policy Sep 26, 2026
150+ Patents, $113 Million Raised, 4 Employees: Inside the Company Betting It Doesn't Need to Run Its Own Trials
Policy Sep 26, 2026
16 States, 7 New Laws, 11 Dead Bills, Only 2 Still Alive: We Scored the 2026 Psychedelic Legislative Session
Research Sep 23, 2026
Which Psychedelic-Company CEO's Pay Actually Matched Their Stock's Performance? We Checked All 10 — Almost None Did.
Research Sep 22, 2026
How Clinical Trials Actually Work — and What It Means for the Psychedelic Industry
Editorial Sep 26, 2026
The "Nibble It" Problem: What Your Doctor Doesn't Have to Tell You About Off-Label Prescriptions
Editorial Sep 22, 2026
Nausea for 12 Hours vs. Sexual Dysfunction for Years: The Side-Effect Math Nobody's Doing on Mental Health Drugs
Policy Sep 21, 2026
19% of American Adults Have Anxiety. Every Drug Treating It Is a Decades-Old Generic — Here's Who Wins If DT120 Changes That
Policy Sep 17, 2026
The Psychedelic Money Graveyard: Renames, Reverse Mergers, and the Companies That Didn't Make It
Policy Sep 11, 2026
The Psychedelic Money Rankings: $11 Billion Public, $1.6 Billion Private, $140 Million From Governments
Wellness Sep 6, 2026
Permafried
Policy Aug 31, 2026
Ibogaine's Flagship Drug Hit a Cardiac Signal and a Lawsuit. A Different Drug Is Now Leading.
Policy Aug 28, 2026
Ketamine Has More Patents Than Any Compound We Track. So Why Isn't Big Pharma More Interested?
Policy Aug 28, 2026
Altitude Intelligence Brief: Who's Actually Making Money on Depression, Anxiety, and PTSD
Policy Aug 26, 2026
Psychedelics in Uniform: What the Military Did to Soldiers, and What the VA Is Now Asking of Veterans
Policy Aug 26, 2026
LSD Has 14 Patents in Our Tracker. The Company Closest to Approval Owns One.
Policy Aug 24, 2026
The 5-MeO-DMT Patent Race Has a Twist: The Clinical Leader Barely Owns Any of It
Policy Aug 20, 2026
Psilocybin Has 223 Patents in Play. Here's Who Actually Holds Them.
Policy Aug 17, 2026
677 Patents and One FDA Rejection: Mapping the Psychedelic Drug Pipeline
Wellness Aug 11, 2026
I Flushed My Antidepressants in Paradise. I Got Lucky.
Neuroscience Aug 10, 2026
Quick Trip or Daily Practice: The Brain Doesn't Care How You Get There
Editorial Jul 30, 2026
Kambo: The Ceremony That Promises Purification and Delivers Peril
Wellness Jul 29, 2026
I Thought I'd Walked Into a Retirement Community. What I Found Was a Masterclass in How the Brain Stays Young
Research Jul 29, 2026
Eli Lilly Just Paid $3.8 Billion for the Same Molecule People Get From a Toad
Personal Story Jul 31, 2026
Holding Your Breath On Purpose
Research Jul 29, 2026
Everyone Knows Which Pill They Got. The FDA Just Said What To Do About It.
Personal Story Apr 4, 2026
Love Yourself Five Times: How Psilocybin Changed My Life
Psychedelic Medicine Jul 7, 2026
The Next Psilocybin Question Is Not Hype. It Is Evidence, Timing, and Review.
Neuroscience Mar 28, 2026
Fear Is Not a Character Flaw. It's Architecture.
Neuroscience Mar 21, 2026
Three Paths to a Healthier Brain: Learning, Meditation, and Psychedelics
Policy Mar 14, 2026
Clinical vs. Consumer: Navigating the New Psilocybin Landscape
Editorial Mar 7, 2026
What Is Evidence-Based Healing? A Guide to Altitude Global's Standards
Personal Story Feb 28, 2026
The God Molecule and the Spilled Milk
Research Feb 14, 2026
The Clinical Revolution: Psilocybin and 5-MeO-DMT Move from Underground to Evidence-Based Medicine
Latest News
See AllPsychedelics Oct 10, 2026
The NYT Put Numbers on Ketamine's Danger Zone: A Clinical Dose Is 30–150mg, Recreational Users Reported Taking 1,000
Regulatory Oct 9, 2026
The FDA Just Cleared Its First-Ever US Trial of an Ibogaine Derivative
Regulatory Oct 7, 2026
The US Is Funding Its First Ibogaine Trials. The FDA Wants 36 Hours of Cardiac Monitoring First.
Neuroscience Oct 6, 2026
A New Study Found Psychedelic Use Near Political Conventions Tracked With More Support for Partisan Violence
Psychedelics Oct 6, 2026
The Same Thing That Makes Ketamine a Breakthrough Antidepressant Makes It Dangerous Without Consent
Regulatory Oct 5, 2026
The DEA Wants to Schedule I 5 Tryptamines. One Already Has FDA Breakthrough Therapy Status.
Regulatory Sep 28, 2026
The Psilocybin Rescheduling Petition Has Been Sitting at HHS for Over a Year With No Word
Psychedelics Sep 28, 2026
A Second Dose of AtaiBeckley's 5-MeO-DMT Drug Also Beat Depression, Trial Data Shows
Product of the Day
Calm
Sleep more. Stress less. Live better. The #1 app for sleep, meditation and relaxation.
Encyclopedia
Set and Setting
Mindset and environment shaping the experience.
Example: "Setting" isn't just ambiance — our reporting on overseas clinic safety found that poor setting (unscreened staff, absent medical oversight, patients dosed without preparation) was a common thread across the worst documented outcomes, not just an aesthetic afterthought.
Aa-Zz
Join the Circle
Access the inner sanctum of Altitude. Weekly digests on neuroscience, early access to retreat bookings, and exclusive product drops.
Free Membership • Unsubscribe Anytime